Pathways Bioscience Dietary Supplement Selected for Testing by National Institute on Aging
Pathways Bioscience’s PB125™ dietary supplement has been selected by the NIA for use in a multi-institutional study to measure its effects on aging.
Aurora, Colorado, May 17, 2018 (PRWeb)—Pathways Bioscience LLC, a biomedical sciences company focused on discovering and developing small molecule drugs and dietary supplements that act on gene transcription pathways, announced today that the National Institute on Aging (NIA) of the US National Institutes of Health (NIH) has selected its Nrf2 activating dietary supplement PB125TM for study in their Interventions Testing Program (ITP) to evaluate the effects of dietary Nrf2 activation on aging and longevity.
"We are honored to be collaborating with the NIA on their longstanding program to evaluate interventions for anti-aging benefits, testing the effects of our potent dietary Nrf2 activator PB125 for benefits during aging. This builds on prior success with dietary Nrf2 activation increasing male mice median longevity in the program, extending into our new, more potent combinations of phytochemical Nrf2 activators" said Joe M. McCord, PhD, Co-founder and scientific leader of Pathways Bioscience.
Selection of test agents for the NIA’s ITP program is competitive, with only a few candidate interventions selected for study each year, based on their potential for beneficial effects on lifespan and healthspan. The candidate interventions include pharmaceuticals, dietary supplements, and other approaches. The experiments are conducted in the three ITP research laboratories at Jackson Laboratories, the University of Michigan, and the University of Texas Health Sciences Center at San Antonio.
“Inclusion in the ITP program is a major step forward for Pathways Bioscience,” said Brooks M. Hybertson, PhD, President and CEO of Pathways Bioscience. “Only a small number of agents that are deemed to hold promise for supporting longevity and healthy aging are selected each year, so the inclusion of PB125 in this competitive program is both an honor and validation of our scientific approach to developing new products that act on the Nrf2 pathway.”
The research reported above is in the ITP Cohort 13 supported by the NIA of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About Pathways Bioscience
Pathways Bioscience LLC is a biomedical sciences company focused on discovering and developing new agents, both small molecule drugs and dietary supplements, that influence gene expression pathways and exert beneficial effects, with particular emphasis on the Nuclear Factor, Erythroid 2 Like 2 (NFE2L2, or Nrf2) gene transcription factor, known as the master regulator of cell protection mechanisms. These activities are based on the concept that the best way to improve healthspan and overcome the health and wellness problems associated with aging is to support the body’s own defense mechanisms that allow it to normalize, protect, and heal itself. The company's headquarters are in Aurora, Colorado. For further information regarding Pathways Bioscience, LLC, please visit the Company’s Website at www.pathwaysbio.com.
The National Institute on Aging is the US federal government's lead agency for scientific research on aging. It leads a broad scientific effort to understand the nature of aging and to extend the healthy, active years of life. NIA is one of the 27 Institutes and Centers of the U.S. National Institutes of Health (NIH). For more information about NIA and its ITP, visit www.nia.nih.gov or https://www.nia.nih.gov/research/dab/interventions-testing-program-itp.
NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.